Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности повышения эффективности эрадикации Helicobacter pylori
Возможности повышения эффективности эрадикации Helicobacter pylori
Казюлин А.Н. Возможности повышения эффективности эрадикации Helicobacter pylori. Consilium Medicum. 2015; 17 (8): 8–14. DOI: 10.26442/2075-1753_2015.8.8-14
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статья обзорного типа, посвященная одной из ведущих проблем гастроэнтерологии – повышению эффективности эрадикационной терапии (ЭТ). На основании анализа результатов рандомизированных клинических исследований, метаанализов данных работ, рекомендаций экспертов Маастрихт IV и российских гастроэнтерологических сообществ определен ряд путей оптимизации ЭТ, среди них: учет резистентности Helicobacter pylori к антибиотикам в конкретном регионе, пролонгация ЭТ, введение препаратов висмута четвертым компонентом в стандартную схему ЭТ, использование последовательной схемы ЭТ, тройной ЭТ с левофлоксацином, двойных доз более мощных ингибиторов протонной помпы, пробиотиков и, в частности, Saccharomyces boulardii при проведении ЭТ, позволяющее не только существенно уменьшить частоту нежелательных явлений, но и увеличить эффективность стандартных схем.
Ключевые слова: эрадикация Helicobacter pylori, ингибиторы протонной помпы, препараты висмута, антибиотики, пробиотики, Saccharomyces boulardii.
Ключевые слова: эрадикация Helicobacter pylori, ингибиторы протонной помпы, препараты висмута, антибиотики, пробиотики, Saccharomyces boulardii.
________________________________________________
Article type overview, dedicated one of the leading problems of gastroenterology – improve the effectiveness of eradication therapy (ET). Based on the analysis of the results of randomized clinical trials, meta-analyses of these works, expert advice of Maastricht IV and Russian gastroenterological community the authors have identified a number of ways to optimize the ET, including: accounting resistant Helicobacter pylori to antibiotics in a particular region, extension ET administration of drugs bismuth fourth component in the standard scheme ET, using sequential circuit ET, ET levofloxacin triple, double doses of more potent proton pump inhibitors, probiotics and in particular, Saccharomyces boulardii during ET allows not only significantly reduce the incidence of adverse events, but also to increase the efficiency of standard circuits.
Key words: eradication of Helicobacter pylori, proton pump inhibitors, bismuth preparations, antibiotics, probiotics, Saccharomyces boulardii.
Key words: eradication of Helicobacter pylori, proton pump inhibitors, bismuth preparations, antibiotics, probiotics, Saccharomyces boulardii.
Полный текст
Список литературы
1. Калинин А.В. Хронический гастрит. Гастроэнтерология и гепатология: диагностика и лечение. М.: Миклош, 2007; с. 59–92. / Kalinin A.V. Khronicheskii gastrit. Gastroenterologiia i gepatologiia: diagnostika i lechenie. M.: Miklosh, 2007; s. 59–92. [in Russian]
2. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М.: ГЭОТАР-Медиа, 2015. / Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
3. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010; 15 (Suppl. 1): 1–6.
4. Tonkic A, Tonkic M, Lehours P, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 1–8.
5. Лазебник Л.Б., Васильев Ю.В., Щербаков П.Л. и др. Helicobacter pylori: распространенность, диагностика и лечение. Экспериментальная и клиническая гастроэнтерология. 2010; 2: 3–7. / Lazebnik L.B., Vasil'ev Iu.V., Shcherbakov P.L. i dr. Helicobacter pylori: rasprostranennost', diagnostika i lechenie. Eksperimental'naia i klinicheskaia gastroenterologiia. 2010; 2: 3–7. [in Russian]
6. Герман С.В., Зыкова И.Е., Модестова А.В., Ермаков Н.В. Распространенность инфекции H. pylori среди населения Москвы. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2010; 2: 25–30. / German S.V., Zykova I.E., Modestova A.V., Ermakov N.V. Rasprostranennost' infektsii H. pylori sredi naseleniia Moskvy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 2: 25–30. [in Russian]
7. Барышникова Н.В., Ткаченко Е.И., Успенский Ю.П. Современные аспекты состояния проблемы Helicobacter pylori-ассоциированных заболеваний. В кн.: Гастроэнтерология. Болезни взрослых. Под общ. ред. Л.Б.Лазебника, П.Л.Щербакова. М.: МК, 2011; с. 103. / Baryshnikova N.V., Tkachenko E.I., Uspenskii Iu.P. Sovremennye aspekty sostoianiia problemy Helicobacter pylori-assotsiirovannykh zabolevanii. V kn.: Gastroenterologiia. Bolezni vzroslykh. Pod obshch. red. L.B.Lazebnika, P.L.Shcherbakova. M.: MK, 2011; s. 103. [in Russian]
8. Цуканов В.В., Хоменко О.В., Ржавичева О.С. и др. Распространенность Helicobacter pylori и ГЭРБ у монголоидов и европеоидов восточной Сибири. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2009; 19 (3): 38–41. / Tsukanov V.V., Khomenko O.V., Rzhavicheva O.S. i dr. Rasprostranennost' Helicobacter pylori i GERB u mongoloidov i evropeoidov vostochnoi Sibiri. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 19 (3): 38–41. [in Russian]
9. Graham DY, Fischbach L. Helicobacter pylori infection. N Engl J Med 2010; 363 (6): 595–6.
10. Лоранская И.Д., Ракитская Л.Г., Мамедова Л.Д. Проблемы лечения хеликобактерной инфекции. РМЖ. 2013; 31: 1638–41. / Loranskaia I.D., Rakitskaia L.G., Mamedova L.D. Problemy lecheniia khelikobakternoi infektsii. RMZh. 2013; 31: 1638–41. [in Russian]
11. Ивашкин В.Т., Шептулин А.А., Лапина Т.А. Хронический гастрит, вызванный инфекцией Helicobacter pylori: диагностика, клиническое значение, прогноз. Пособие для врачей. РГА. М., 2009. / Ivashkin V.T., Sheptulin A.A., Lapina T.A. Khronicheskii gastrit, vyzvannyi infektsiei Helicobacter pylori: diagnostika, klinicheskoe znachenie, prognoz. Posobie dlia vrachei. RGA. M., 2009. [in Russian]
12. Лазебник Л.Б., Бордин Д.С. и др. Хронический гастрит. Методические рекомендации. М.: ЦНИИГ, 2011. / Lazebnik L.B., Bordin D.S. i dr. Khronicheskii gastrit. Metodicheskie rekomendatsii. M.: TsNIIG, 2011. [in Russian]
13. Delahay R, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 9–15.
14. Старостин Б.Д. Повышение эффективности эрадикации Helicobacter pylori при Helicobacter pylori-ассоциированных заболеваниях. Практические рекомендации и схемы терапии. Под ред. Е.И.Ткаченко. СПб.: Инфо Ол, 2015. / Starostin B.D. Povyshenie effektivnosti eradikatsii Helicobacter pylori pri Helicobacter pylori-assotsiirovannykh zabolevaniiakh. Prakticheskie rekomendatsii i skhemy terapii. Pod red. E.I.Tkachenko. SPb.: Info Ol, 2015. [in Russian]
15. Malfertheiner P, Megraud F, O’Morain CA et al. The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–64.
16. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Комитет по подготовке проекта рекомендаций: Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. РЖГГК. 2012; 22 (1): 87–9. / Rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Komitet po podgotovke proekta rekomendatsii: Ivashkin V.T., Maev I.V., Lapina T.L., Sheptulin A.A. RZhGGK. 2012; 22 (1): 87–9. [in Russian]
17. Лазебник Л.Б., Ткаченко Е.И., Абдулхаков Р.А. и др. Стандарты диагностики и лечения кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (пятое Московское соглашение). Эксперим. и клин. Гастроэнтерология. 2013; 5: 3–11. / Lazebnik L.B., Tkachenko E.I., Abdulkhakov R.A. i dr. Standarty diagnostiki i lecheniia kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevanii (piatoe Moskovskoe soglashenie). Eksperim. i klin. gastroenterologiia. 2013; 5: 3–11. [in Russian]
18. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102 (8): 1808–25.
19. Graham DY, Fiscbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. GUT 2010; 59 (8): 1143–53.
20. Маев И.В., Самсонов А.А., Коровина Т.И. и др. Висмута трикалия дицитрат повышает эффективность антихеликобактерной терапии первой линии. Эксперим. и клин. гастроэнтерология. 2012; 8: 92–7. / Maev I.V., Samsonov A.A., Korovina T.I. i dr. Vismuta trikaliia ditsitrat povyshaet effektivnost' antikhelikobakternoi terapii pervoi linii. Eksperim. i klin. gastroenterologiia. 2012; 8: 92–7. [in Russian]
21. Lazebnik LB, Masharova AA, Bordin DS, Khomeriki SG. Influence of Bismuth on Gastritis Healing and Effectiveness of Helicobacter pylori Eradication. Helicobacter 2010; 15: 343.
22. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34 (11–12): 1255–68.
23. Лапина Т.Л., Мутигулина Э.Р., Ивашкин В.Т. Рациональный выбор эрадикационной терапии инфекции Helicobacter pylori. РЖГГК. 2013; 23 (5): 74–80. / Lapina T.L., Mutigulina E.R., Ivashkin V.T. Ratsional'nyi vybor eradikatsionnoi terapii infektsii Helicobacter pylori. RZhGGK. 2013; 23 (5): 74–80. [in Russian]
24. Sun Q, Liang X, Zheng Q et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15 (3): 233–8.
25. Yoon JH, Baik GH, Kim YS et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver 2012; 6 (4): 434–9.
26. Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Эксперим. и клин. гастроэнтерология. 2012; 5: 99–106. / Bordin D.S., Masharova A.A., Khomeriki S.G. Khronicheskii gastrit: sovremennyi vzgliad na staruiu problemu. Eksperim. i klin. gastroenterologiia. 2012; 5: 99–106. [in Russian]
27. Yuan Y, Ford AC, Khan KJ. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
28. Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013; 73 (8): 815–24.
29. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 7 (347): f4587.
30. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23 (1): 35–44.
31. Кучерявый Ю.А., Баркалова Е.В. Выраженность кислотосупрессивного действия ингибиторов протонной помпы и эффективность современных эрадикационных схем. Фарматека. 2013; 10: 11–7. / Kucheriavyi Iu.A., Barkalova E.V. Vyrazhennost' kislotosupressivnogo deistviia ingibitorov protonnoi pompy i effektivnost' sovremennykh eradikatsionnykh skhem. Farmateka. 2013; 10: 11–7. [in Russian]
32. Scott D, Weeks D, Melchers K et al. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl. 1): S56–S60.
33. Sugimoto M, Furuta T, Shirai N et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12 (4): 317–23.
34. Anagnostopoulos GK, Tsiakos S, Margantinis G et al. Esomeprazole versus omeprazole for the eradi- cation of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004; 38 (6): 503–6.
35. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28 (7): 868–77.
36. Кучерявый Ю.А., Баркалова Е.В. Двойные дозы ингибиторов протонной помпы – путь повышения эффективности тройной антихеликобактерной терапии первой линии. Лечебное дело. 2012; 1: 36–42. / Kucheriavyi Iu.A., Barkalova E.V. Dvoinye dozy ingibitorov protonnoi pompy – put' povysheniia effektivnosti troinoi antikhelikobakternoi terapii pervoi linii. Lechebnoe delo. 2012; 1: 36–42. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first- generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
38. Саблин О.А., Михайлов Н.В., Юрин М.В. и др. Факторы, определяющие эффективность эрадикационной терапии Helicobacter pylori-ассоциированных заболеваний. Consilium Medicum. Гастроэнтерология (Прил.). 2011; 2: 3–10. Sablin O.A., Mikhailov N.V., Iurin M.V. i dr. Faktory, opredeliaiushchie effektivnost' eradikatsionnoi terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterology (Suppl.). 2011; 2: 3–10. [in Russian]
39. Бордин Д.С., Колбасников С.В., Кононова А.Г. Роль пробиотиков в лечении заболеваний, ассоциированных с Н. pylori. Врач. 2015; 3. / Bordin D.S., Kolbasnikov S.V., Kononova A.G. Rol' probiotikov v lechenii zabolevanii, assotsiirovannykh s N. pylori. Vrach. 2015; 3. [in Russian]
40. Ивашкина, Н.Ю., Самсонов А.А., Казюлин А.Н. и др. Распространенность антибиотико-ассоциированной диареи. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2008; 5: 58. / Ivashkina, N.Iu., Samsonov A.A., Kaziulin A.N. i dr. Rasprostranennost' antibiotiko-assotsiirovannoi diarei. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 5: 58. [in Russian]
41. Cremonini F, di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16 (8): 1461–7.
42. McFarland LV. Metaanalysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006 (Suppl.); 101 (4): 812–22.
43 Маев И.В., Ивашкина Н.Ю., Самсонов А.А. и др. Возможности профилактики идиопатической анитибиотикоассоциированной диареи у взрослых. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2009; 2: 75–8. / Maev I.V., Ivashkina N.Iu., Samsonov A.A. i dr. Vozmozhnosti profilaktiki idiopaticheskoi anitibiotikoassotsiirovannoi diarei u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 2: 75–8. [in Russian]
44. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137 (8): 812S–818S.
45. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20 (6): 1450–69.
46. Guarner F, Khan AG, Garisch J et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012; 46 (6): 468–81.
47. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069–79.
48. Дехнич Н.Н., Бобылев А.А. Saccharomyces boulardii в терапии Helicobacter pylori-ассоциированных заболеваний. Consilium Medicum. Гастроэнтерология (Прил.). 2015; 1: 39–42. / Dekhnich N.N., Bobylev A.A. Saccharomyces boulardii v terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterologiia (Suppl.). 2015; 1: 39–42. [in Russian]
49. Шифрин О.С. Антибиотикоассоциированные поражения кишечника. Consilium Medicum. 2005; 4. / Shifrin O.S. Antibiotikoassotsiirovannye porazheniia kishechnika. Consilium Medicum. 2005; 7 (4). [in Russian]
50. Goulet O. Saccharomyces boulardii. Arch Pediatr 2009; 16 (Hors serie N 1): 1–14.
51. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16 (18): 2202–22.
52. Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for a2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 2014; 122 (10): 941–50.
53. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
54. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221–38.
55. Midolo PD, Lambert JR, Hull R et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79: 475–9.
56. Cremonini F, di Caro S, Covino M et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
57. Duman DG, Bor S, Oztemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
58. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
59. Szaajewska H, Horvat A, Kolodziei M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41 (12): 1237–45.
2. Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
3. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010; 15 (Suppl. 1): 1–6.
4. Tonkic A, Tonkic M, Lehours P, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 1–8.
5. Lazebnik L.B., Vasil'ev Iu.V., Shcherbakov P.L. i dr. Helicobacter pylori: rasprostranennost', diagnostika i lechenie. Eksperimental'naia i klinicheskaia gastroenterologiia. 2010; 2: 3–7. [in Russian]
6. German S.V., Zykova I.E., Modestova A.V., Ermakov N.V. Rasprostranennost' infektsii H. pylori sredi naseleniia Moskvy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 2: 25–30. [in Russian]
7. Baryshnikova N.V., Tkachenko E.I., Uspenskii Iu.P. Sovremennye aspekty sostoianiia problemy Helicobacter pylori-assotsiirovannykh zabolevanii. V kn.: Gastroenterologiia. Bolezni vzroslykh. Pod obshch. red. L.B.Lazebnika, P.L.Shcherbakova. M.: MK, 2011; s. 103. [in Russian]
8. Tsukanov V.V., Khomenko O.V., Rzhavicheva O.S. i dr. Rasprostranennost' Helicobacter pylori i GERB u mongoloidov i evropeoidov vostochnoi Sibiri. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 19 (3): 38–41. [in Russian]
9. Graham DY, Fischbach L. Helicobacter pylori infection. N Engl J Med 2010; 363 (6): 595–6.
10. Loranskaia I.D., Rakitskaia L.G., Mamedova L.D. Problemy lecheniia khelikobakternoi infektsii. RMZh. 2013; 31: 1638–41. [in Russian]
11. Ivashkin V.T., Sheptulin A.A., Lapina T.A. Khronicheskii gastrit, vyzvannyi infektsiei Helicobacter pylori: diagnostika, klinicheskoe znachenie, prognoz. Posobie dlia vrachei. RGA. M., 2009. [in Russian]
12. Lazebnik L.B., Bordin D.S. i dr. Khronicheskii gastrit. Metodicheskie rekomendatsii. M.: TsNIIG, 2011. [in Russian]
13. Delahay R, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 9–15.
14. Starostin B.D. Povyshenie effektivnosti eradikatsii Helicobacter pylori pri Helicobacter pylori-assotsiirovannykh zabolevaniiakh. Prakticheskie rekomendatsii i skhemy terapii. Pod red. E.I.Tkachenko. SPb.: Info Ol, 2015. [in Russian]
15. Malfertheiner P, Megraud F, O’Morain CA et al. The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–64.
16. Rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Komitet po podgotovke proekta rekomendatsii: Ivashkin V.T., Maev I.V., Lapina T.L., Sheptulin A.A. RZhGGK. 2012; 22 (1): 87–9. [in Russian]
17. Lazebnik L.B., Tkachenko E.I., Abdulkhakov R.A. i dr. Standarty diagnostiki i lecheniia kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevanii (piatoe Moskovskoe soglashenie). Eksperim. i klin. gastroenterologiia. 2013; 5: 3–11. [in Russian]
18. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102 (8): 1808–25.
19. Graham DY, Fiscbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. GUT 2010; 59 (8): 1143–53.
20. Maev I.V., Samsonov A.A., Korovina T.I. i dr. Vismuta trikaliia ditsitrat povyshaet effektivnost' antikhelikobakternoi terapii pervoi linii. Eksperim. i klin. gastroenterologiia. 2012; 8: 92–7. [in Russian]
21. Lazebnik LB, Masharova AA, Bordin DS, Khomeriki SG. Influence of Bismuth on Gastritis Healing and Effectiveness of Helicobacter pylori Eradication. Helicobacter 2010; 15: 343.
22. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34 (11–12): 1255–68.
23. Lapina T.L., Mutigulina E.R., Ivashkin V.T. Ratsional'nyi vybor eradikatsionnoi terapii infektsii Helicobacter pylori. RZhGGK. 2013; 23 (5): 74–80. [in Russian]
24. Sun Q, Liang X, Zheng Q et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15 (3): 233–8.
25. Yoon JH, Baik GH, Kim YS et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver 2012; 6 (4): 434–9.
26. Bordin D.S., Masharova A.A., Khomeriki S.G. Khronicheskii gastrit: sovremennyi vzgliad na staruiu problemu. Eksperim. i klin. gastroenterologiia. 2012; 5: 99–106. [in Russian]
27. Yuan Y, Ford AC, Khan KJ. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
28. Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013; 73 (8): 815–24.
29. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 7 (347): f4587.
30. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23 (1): 35–44.
31. Kucheriavyi Iu.A., Barkalova E.V. Vyrazhennost' kislotosupressivnogo deistviia ingibitorov protonnoi pompy i effektivnost' sovremennykh eradikatsionnykh skhem. Farmateka. 2013; 10: 11–7. [in Russian]
32. Scott D, Weeks D, Melchers K et al. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl. 1): S56–S60.
33. Sugimoto M, Furuta T, Shirai N et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12 (4): 317–23.
34. Anagnostopoulos GK, Tsiakos S, Margantinis G et al. Esomeprazole versus omeprazole for the eradi- cation of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004; 38 (6): 503–6.
35. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28 (7): 868–77.
36. Kucheriavyi Iu.A., Barkalova E.V. Dvoinye dozy ingibitorov protonnoi pompy – put' povysheniia effektivnosti troinoi antikhelikobakternoi terapii pervoi linii. Lechebnoe delo. 2012; 1: 36–42. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first- generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
38. Sablin O.A., Mikhailov N.V., Iurin M.V. i dr. Faktory, opredeliaiushchie effektivnost' eradikatsionnoi terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterology (Suppl.). 2011; 2: 3–10. [in Russian]
39. Bordin D.S., Kolbasnikov S.V., Kononova A.G. Rol' probiotikov v lechenii zabolevanii, assotsiirovannykh s N. pylori. Vrach. 2015; 3. [in Russian]
40. Ivashkina, N.Iu., Samsonov A.A., Kaziulin A.N. i dr. Rasprostranennost' antibiotiko-assotsiirovannoi diarei. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 5: 58. [in Russian]
41. Cremonini F, di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16 (8): 1461–7.
42. McFarland LV. Metaanalysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006 (Suppl.); 101 (4): 812–22.
43. Maev I.V., Ivashkina N.Iu., Samsonov A.A. i dr. Vozmozhnosti profilaktiki idiopaticheskoi anitibiotikoassotsiirovannoi diarei u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 2: 75–8. [in Russian]
44. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137 (8): 812S–818S.
45. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20 (6): 1450–69.
46. Guarner F, Khan AG, Garisch J et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012; 46 (6): 468–81.
47. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069–79.
48. Dekhnich N.N., Bobylev A.A. Saccharomyces boulardii v terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterologiia (Suppl.). 2015; 1: 39–42. [in Russian]
49. Shifrin O.S. Antibiotikoassotsiirovannye porazheniia kishechnika. Consilium Medicum. 2005; 7 (4). [in Russian]
50. Goulet O. Saccharomyces boulardii. Arch Pediatr 2009; 16 (Hors serie N 1): 1–14.
51. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16 (18): 2202–22.
52. Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for a2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 2014; 122 (10): 941–50.
53. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
54. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221–38.
55. Midolo PD, Lambert JR, Hull R et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79: 475–9.
56. Cremonini F, di Caro S, Covino M et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
57. Duman DG, Bor S, Oztemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
58. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
59. Szaajewska H, Horvat A, Kolodziei M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41 (12): 1237–45.
2. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М.: ГЭОТАР-Медиа, 2015. / Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
3. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010; 15 (Suppl. 1): 1–6.
4. Tonkic A, Tonkic M, Lehours P, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 1–8.
5. Лазебник Л.Б., Васильев Ю.В., Щербаков П.Л. и др. Helicobacter pylori: распространенность, диагностика и лечение. Экспериментальная и клиническая гастроэнтерология. 2010; 2: 3–7. / Lazebnik L.B., Vasil'ev Iu.V., Shcherbakov P.L. i dr. Helicobacter pylori: rasprostranennost', diagnostika i lechenie. Eksperimental'naia i klinicheskaia gastroenterologiia. 2010; 2: 3–7. [in Russian]
6. Герман С.В., Зыкова И.Е., Модестова А.В., Ермаков Н.В. Распространенность инфекции H. pylori среди населения Москвы. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2010; 2: 25–30. / German S.V., Zykova I.E., Modestova A.V., Ermakov N.V. Rasprostranennost' infektsii H. pylori sredi naseleniia Moskvy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 2: 25–30. [in Russian]
7. Барышникова Н.В., Ткаченко Е.И., Успенский Ю.П. Современные аспекты состояния проблемы Helicobacter pylori-ассоциированных заболеваний. В кн.: Гастроэнтерология. Болезни взрослых. Под общ. ред. Л.Б.Лазебника, П.Л.Щербакова. М.: МК, 2011; с. 103. / Baryshnikova N.V., Tkachenko E.I., Uspenskii Iu.P. Sovremennye aspekty sostoianiia problemy Helicobacter pylori-assotsiirovannykh zabolevanii. V kn.: Gastroenterologiia. Bolezni vzroslykh. Pod obshch. red. L.B.Lazebnika, P.L.Shcherbakova. M.: MK, 2011; s. 103. [in Russian]
8. Цуканов В.В., Хоменко О.В., Ржавичева О.С. и др. Распространенность Helicobacter pylori и ГЭРБ у монголоидов и европеоидов восточной Сибири. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2009; 19 (3): 38–41. / Tsukanov V.V., Khomenko O.V., Rzhavicheva O.S. i dr. Rasprostranennost' Helicobacter pylori i GERB u mongoloidov i evropeoidov vostochnoi Sibiri. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 19 (3): 38–41. [in Russian]
9. Graham DY, Fischbach L. Helicobacter pylori infection. N Engl J Med 2010; 363 (6): 595–6.
10. Лоранская И.Д., Ракитская Л.Г., Мамедова Л.Д. Проблемы лечения хеликобактерной инфекции. РМЖ. 2013; 31: 1638–41. / Loranskaia I.D., Rakitskaia L.G., Mamedova L.D. Problemy lecheniia khelikobakternoi infektsii. RMZh. 2013; 31: 1638–41. [in Russian]
11. Ивашкин В.Т., Шептулин А.А., Лапина Т.А. Хронический гастрит, вызванный инфекцией Helicobacter pylori: диагностика, клиническое значение, прогноз. Пособие для врачей. РГА. М., 2009. / Ivashkin V.T., Sheptulin A.A., Lapina T.A. Khronicheskii gastrit, vyzvannyi infektsiei Helicobacter pylori: diagnostika, klinicheskoe znachenie, prognoz. Posobie dlia vrachei. RGA. M., 2009. [in Russian]
12. Лазебник Л.Б., Бордин Д.С. и др. Хронический гастрит. Методические рекомендации. М.: ЦНИИГ, 2011. / Lazebnik L.B., Bordin D.S. i dr. Khronicheskii gastrit. Metodicheskie rekomendatsii. M.: TsNIIG, 2011. [in Russian]
13. Delahay R, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 9–15.
14. Старостин Б.Д. Повышение эффективности эрадикации Helicobacter pylori при Helicobacter pylori-ассоциированных заболеваниях. Практические рекомендации и схемы терапии. Под ред. Е.И.Ткаченко. СПб.: Инфо Ол, 2015. / Starostin B.D. Povyshenie effektivnosti eradikatsii Helicobacter pylori pri Helicobacter pylori-assotsiirovannykh zabolevaniiakh. Prakticheskie rekomendatsii i skhemy terapii. Pod red. E.I.Tkachenko. SPb.: Info Ol, 2015. [in Russian]
15. Malfertheiner P, Megraud F, O’Morain CA et al. The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–64.
16. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Комитет по подготовке проекта рекомендаций: Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. РЖГГК. 2012; 22 (1): 87–9. / Rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Komitet po podgotovke proekta rekomendatsii: Ivashkin V.T., Maev I.V., Lapina T.L., Sheptulin A.A. RZhGGK. 2012; 22 (1): 87–9. [in Russian]
17. Лазебник Л.Б., Ткаченко Е.И., Абдулхаков Р.А. и др. Стандарты диагностики и лечения кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (пятое Московское соглашение). Эксперим. и клин. Гастроэнтерология. 2013; 5: 3–11. / Lazebnik L.B., Tkachenko E.I., Abdulkhakov R.A. i dr. Standarty diagnostiki i lecheniia kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevanii (piatoe Moskovskoe soglashenie). Eksperim. i klin. gastroenterologiia. 2013; 5: 3–11. [in Russian]
18. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102 (8): 1808–25.
19. Graham DY, Fiscbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. GUT 2010; 59 (8): 1143–53.
20. Маев И.В., Самсонов А.А., Коровина Т.И. и др. Висмута трикалия дицитрат повышает эффективность антихеликобактерной терапии первой линии. Эксперим. и клин. гастроэнтерология. 2012; 8: 92–7. / Maev I.V., Samsonov A.A., Korovina T.I. i dr. Vismuta trikaliia ditsitrat povyshaet effektivnost' antikhelikobakternoi terapii pervoi linii. Eksperim. i klin. gastroenterologiia. 2012; 8: 92–7. [in Russian]
21. Lazebnik LB, Masharova AA, Bordin DS, Khomeriki SG. Influence of Bismuth on Gastritis Healing and Effectiveness of Helicobacter pylori Eradication. Helicobacter 2010; 15: 343.
22. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34 (11–12): 1255–68.
23. Лапина Т.Л., Мутигулина Э.Р., Ивашкин В.Т. Рациональный выбор эрадикационной терапии инфекции Helicobacter pylori. РЖГГК. 2013; 23 (5): 74–80. / Lapina T.L., Mutigulina E.R., Ivashkin V.T. Ratsional'nyi vybor eradikatsionnoi terapii infektsii Helicobacter pylori. RZhGGK. 2013; 23 (5): 74–80. [in Russian]
24. Sun Q, Liang X, Zheng Q et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15 (3): 233–8.
25. Yoon JH, Baik GH, Kim YS et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver 2012; 6 (4): 434–9.
26. Бордин Д.С., Машарова А.А., Хомерики С.Г. Хронический гастрит: современный взгляд на старую проблему. Эксперим. и клин. гастроэнтерология. 2012; 5: 99–106. / Bordin D.S., Masharova A.A., Khomeriki S.G. Khronicheskii gastrit: sovremennyi vzgliad na staruiu problemu. Eksperim. i klin. gastroenterologiia. 2012; 5: 99–106. [in Russian]
27. Yuan Y, Ford AC, Khan KJ. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
28. Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013; 73 (8): 815–24.
29. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 7 (347): f4587.
30. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23 (1): 35–44.
31. Кучерявый Ю.А., Баркалова Е.В. Выраженность кислотосупрессивного действия ингибиторов протонной помпы и эффективность современных эрадикационных схем. Фарматека. 2013; 10: 11–7. / Kucheriavyi Iu.A., Barkalova E.V. Vyrazhennost' kislotosupressivnogo deistviia ingibitorov protonnoi pompy i effektivnost' sovremennykh eradikatsionnykh skhem. Farmateka. 2013; 10: 11–7. [in Russian]
32. Scott D, Weeks D, Melchers K et al. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl. 1): S56–S60.
33. Sugimoto M, Furuta T, Shirai N et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12 (4): 317–23.
34. Anagnostopoulos GK, Tsiakos S, Margantinis G et al. Esomeprazole versus omeprazole for the eradi- cation of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004; 38 (6): 503–6.
35. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28 (7): 868–77.
36. Кучерявый Ю.А., Баркалова Е.В. Двойные дозы ингибиторов протонной помпы – путь повышения эффективности тройной антихеликобактерной терапии первой линии. Лечебное дело. 2012; 1: 36–42. / Kucheriavyi Iu.A., Barkalova E.V. Dvoinye dozy ingibitorov protonnoi pompy – put' povysheniia effektivnosti troinoi antikhelikobakternoi terapii pervoi linii. Lechebnoe delo. 2012; 1: 36–42. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first- generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
38. Саблин О.А., Михайлов Н.В., Юрин М.В. и др. Факторы, определяющие эффективность эрадикационной терапии Helicobacter pylori-ассоциированных заболеваний. Consilium Medicum. Гастроэнтерология (Прил.). 2011; 2: 3–10. Sablin O.A., Mikhailov N.V., Iurin M.V. i dr. Faktory, opredeliaiushchie effektivnost' eradikatsionnoi terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterology (Suppl.). 2011; 2: 3–10. [in Russian]
39. Бордин Д.С., Колбасников С.В., Кононова А.Г. Роль пробиотиков в лечении заболеваний, ассоциированных с Н. pylori. Врач. 2015; 3. / Bordin D.S., Kolbasnikov S.V., Kononova A.G. Rol' probiotikov v lechenii zabolevanii, assotsiirovannykh s N. pylori. Vrach. 2015; 3. [in Russian]
40. Ивашкина, Н.Ю., Самсонов А.А., Казюлин А.Н. и др. Распространенность антибиотико-ассоциированной диареи. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2008; 5: 58. / Ivashkina, N.Iu., Samsonov A.A., Kaziulin A.N. i dr. Rasprostranennost' antibiotiko-assotsiirovannoi diarei. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 5: 58. [in Russian]
41. Cremonini F, di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16 (8): 1461–7.
42. McFarland LV. Metaanalysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006 (Suppl.); 101 (4): 812–22.
43 Маев И.В., Ивашкина Н.Ю., Самсонов А.А. и др. Возможности профилактики идиопатической анитибиотикоассоциированной диареи у взрослых. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2009; 2: 75–8. / Maev I.V., Ivashkina N.Iu., Samsonov A.A. i dr. Vozmozhnosti profilaktiki idiopaticheskoi anitibiotikoassotsiirovannoi diarei u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 2: 75–8. [in Russian]
44. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137 (8): 812S–818S.
45. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20 (6): 1450–69.
46. Guarner F, Khan AG, Garisch J et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012; 46 (6): 468–81.
47. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069–79.
48. Дехнич Н.Н., Бобылев А.А. Saccharomyces boulardii в терапии Helicobacter pylori-ассоциированных заболеваний. Consilium Medicum. Гастроэнтерология (Прил.). 2015; 1: 39–42. / Dekhnich N.N., Bobylev A.A. Saccharomyces boulardii v terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterologiia (Suppl.). 2015; 1: 39–42. [in Russian]
49. Шифрин О.С. Антибиотикоассоциированные поражения кишечника. Consilium Medicum. 2005; 4. / Shifrin O.S. Antibiotikoassotsiirovannye porazheniia kishechnika. Consilium Medicum. 2005; 7 (4). [in Russian]
50. Goulet O. Saccharomyces boulardii. Arch Pediatr 2009; 16 (Hors serie N 1): 1–14.
51. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16 (18): 2202–22.
52. Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for a2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 2014; 122 (10): 941–50.
53. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
54. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221–38.
55. Midolo PD, Lambert JR, Hull R et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79: 475–9.
56. Cremonini F, di Caro S, Covino M et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
57. Duman DG, Bor S, Oztemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
58. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
59. Szaajewska H, Horvat A, Kolodziei M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41 (12): 1237–45.
________________________________________________
2. Maev I.V., Samsonov A.A., Andreev D.N. Bolezni zheludka. M.: GEOTAR-Media, 2015. [in Russian]
3. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010; 15 (Suppl. 1): 1–6.
4. Tonkic A, Tonkic M, Lehours P, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 1–8.
5. Lazebnik L.B., Vasil'ev Iu.V., Shcherbakov P.L. i dr. Helicobacter pylori: rasprostranennost', diagnostika i lechenie. Eksperimental'naia i klinicheskaia gastroenterologiia. 2010; 2: 3–7. [in Russian]
6. German S.V., Zykova I.E., Modestova A.V., Ermakov N.V. Rasprostranennost' infektsii H. pylori sredi naseleniia Moskvy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 2: 25–30. [in Russian]
7. Baryshnikova N.V., Tkachenko E.I., Uspenskii Iu.P. Sovremennye aspekty sostoianiia problemy Helicobacter pylori-assotsiirovannykh zabolevanii. V kn.: Gastroenterologiia. Bolezni vzroslykh. Pod obshch. red. L.B.Lazebnika, P.L.Shcherbakova. M.: MK, 2011; s. 103. [in Russian]
8. Tsukanov V.V., Khomenko O.V., Rzhavicheva O.S. i dr. Rasprostranennost' Helicobacter pylori i GERB u mongoloidov i evropeoidov vostochnoi Sibiri. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 19 (3): 38–41. [in Russian]
9. Graham DY, Fischbach L. Helicobacter pylori infection. N Engl J Med 2010; 363 (6): 595–6.
10. Loranskaia I.D., Rakitskaia L.G., Mamedova L.D. Problemy lecheniia khelikobakternoi infektsii. RMZh. 2013; 31: 1638–41. [in Russian]
11. Ivashkin V.T., Sheptulin A.A., Lapina T.A. Khronicheskii gastrit, vyzvannyi infektsiei Helicobacter pylori: diagnostika, klinicheskoe znachenie, prognoz. Posobie dlia vrachei. RGA. M., 2009. [in Russian]
12. Lazebnik L.B., Bordin D.S. i dr. Khronicheskii gastrit. Metodicheskie rekomendatsii. M.: TsNIIG, 2011. [in Russian]
13. Delahay R, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 9–15.
14. Starostin B.D. Povyshenie effektivnosti eradikatsii Helicobacter pylori pri Helicobacter pylori-assotsiirovannykh zabolevaniiakh. Prakticheskie rekomendatsii i skhemy terapii. Pod red. E.I.Tkachenko. SPb.: Info Ol, 2015. [in Russian]
15. Malfertheiner P, Megraud F, O’Morain CA et al. The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–64.
16. Rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Komitet po podgotovke proekta rekomendatsii: Ivashkin V.T., Maev I.V., Lapina T.L., Sheptulin A.A. RZhGGK. 2012; 22 (1): 87–9. [in Russian]
17. Lazebnik L.B., Tkachenko E.I., Abdulkhakov R.A. i dr. Standarty diagnostiki i lecheniia kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevanii (piatoe Moskovskoe soglashenie). Eksperim. i klin. gastroenterologiia. 2013; 5: 3–11. [in Russian]
18. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102 (8): 1808–25.
19. Graham DY, Fiscbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. GUT 2010; 59 (8): 1143–53.
20. Maev I.V., Samsonov A.A., Korovina T.I. i dr. Vismuta trikaliia ditsitrat povyshaet effektivnost' antikhelikobakternoi terapii pervoi linii. Eksperim. i klin. gastroenterologiia. 2012; 8: 92–7. [in Russian]
21. Lazebnik LB, Masharova AA, Bordin DS, Khomeriki SG. Influence of Bismuth on Gastritis Healing and Effectiveness of Helicobacter pylori Eradication. Helicobacter 2010; 15: 343.
22. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34 (11–12): 1255–68.
23. Lapina T.L., Mutigulina E.R., Ivashkin V.T. Ratsional'nyi vybor eradikatsionnoi terapii infektsii Helicobacter pylori. RZhGGK. 2013; 23 (5): 74–80. [in Russian]
24. Sun Q, Liang X, Zheng Q et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15 (3): 233–8.
25. Yoon JH, Baik GH, Kim YS et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver 2012; 6 (4): 434–9.
26. Bordin D.S., Masharova A.A., Khomeriki S.G. Khronicheskii gastrit: sovremennyi vzgliad na staruiu problemu. Eksperim. i klin. gastroenterologiia. 2012; 5: 99–106. [in Russian]
27. Yuan Y, Ford AC, Khan KJ. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
28. Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013; 73 (8): 815–24.
29. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 7 (347): f4587.
30. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23 (1): 35–44.
31. Kucheriavyi Iu.A., Barkalova E.V. Vyrazhennost' kislotosupressivnogo deistviia ingibitorov protonnoi pompy i effektivnost' sovremennykh eradikatsionnykh skhem. Farmateka. 2013; 10: 11–7. [in Russian]
32. Scott D, Weeks D, Melchers K et al. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl. 1): S56–S60.
33. Sugimoto M, Furuta T, Shirai N et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12 (4): 317–23.
34. Anagnostopoulos GK, Tsiakos S, Margantinis G et al. Esomeprazole versus omeprazole for the eradi- cation of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004; 38 (6): 503–6.
35. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28 (7): 868–77.
36. Kucheriavyi Iu.A., Barkalova E.V. Dvoinye dozy ingibitorov protonnoi pompy – put' povysheniia effektivnosti troinoi antikhelikobakternoi terapii pervoi linii. Lechebnoe delo. 2012; 1: 36–42. [in Russian]
37. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first- generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
38. Sablin O.A., Mikhailov N.V., Iurin M.V. i dr. Faktory, opredeliaiushchie effektivnost' eradikatsionnoi terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterology (Suppl.). 2011; 2: 3–10. [in Russian]
39. Bordin D.S., Kolbasnikov S.V., Kononova A.G. Rol' probiotikov v lechenii zabolevanii, assotsiirovannykh s N. pylori. Vrach. 2015; 3. [in Russian]
40. Ivashkina, N.Iu., Samsonov A.A., Kaziulin A.N. i dr. Rasprostranennost' antibiotiko-assotsiirovannoi diarei. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2008; 5: 58. [in Russian]
41. Cremonini F, di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16 (8): 1461–7.
42. McFarland LV. Metaanalysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006 (Suppl.); 101 (4): 812–22.
43. Maev I.V., Ivashkina N.Iu., Samsonov A.A. i dr. Vozmozhnosti profilaktiki idiopaticheskoi anitibiotikoassotsiirovannoi diarei u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2009; 2: 75–8. [in Russian]
44. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007; 137 (8): 812S–818S.
45. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20 (6): 1450–69.
46. Guarner F, Khan AG, Garisch J et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012; 46 (6): 468–81.
47. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069–79.
48. Dekhnich N.N., Bobylev A.A. Saccharomyces boulardii v terapii Helicobacter pylori-assotsiirovannykh zabolevanii. Consilium Medicum. Gastroenterologiia (Suppl.). 2015; 1: 39–42. [in Russian]
49. Shifrin O.S. Antibiotikoassotsiirovannye porazheniia kishechnika. Consilium Medicum. 2005; 7 (4). [in Russian]
50. Goulet O. Saccharomyces boulardii. Arch Pediatr 2009; 16 (Hors serie N 1): 1–14.
51. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16 (18): 2202–22.
52. Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for a2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 2014; 122 (10): 941–50.
53. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
54. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221–38.
55. Midolo PD, Lambert JR, Hull R et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79: 475–9.
56. Cremonini F, di Caro S, Covino M et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
57. Duman DG, Bor S, Oztemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
58. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
59. Szaajewska H, Horvat A, Kolodziei M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2015; 41 (12): 1237–45.
Авторы
А.Н.Казюлин
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
alexander.kazyulin@yandex.ru
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
alexander.kazyulin@yandex.ru
________________________________________________
A.N.Kazyulin
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
alexander.kazyulin@yandex.ru
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
alexander.kazyulin@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.